AI Article Synopsis

  • The opioid epidemic has led to significant developmental concerns for infants in the U.S., with prenatal opioid exposure linked to cognitive and behavioral issues later in life.
  • This study aims to compare brain measurements of opioid-exposed fetuses with those unexposed using fetal MRI, focusing on biometric data and pregnancy-related assessments.
  • Results indicated that several brain measurements were significantly smaller in opioid-exposed fetuses compared to unexposed ones, suggesting that opioid exposure may adversely affect brain development.

Article Abstract

The opioid epidemic has profoundly affected infants born in the United States, as in utero opioid exposure increases the risk of cognitive and behavioral problems in childhood. Scarce literature has evaluated prenatal brain development in fetuses with opioid exposure in utero (hereafter opioid-exposed fetuses). The purpose of this study is to compare opioid-exposed fetuses and fetuses without opioid exposure (hereafter unexposed fetuses) in terms of 2D biometric measurements of the brain and additional pregnancy-related assessments on fetal MRI. This prospective case-control study included patients in the third trimester of pregnancy who underwent investigational fetal MRI at one of three U.S. academic medical centers from July 1, 2020, through December 31, 2021. Fetuses were classified as opioid exposed or unexposed in utero. Fourteen 2D biometric measurements of the fetal brain were manually assessed and used to derive four indexes. Measurements and indexes were compared between the two groups by use of multivariable linear regression models, which were adjusted for gestational age (GA), fetal sex, and nicotine exposure. Additional pregnancy-related findings on MRI were evaluated. The study included 65 women (mean age, 29.0 ± 5.5 [SD] years). A total of 28 fetuses (mean GA at the time of MRI, 32.2 ± 2.5 weeks) were opioid-exposed, and 37 fetuses (mean GA at the time of MRI, 31.9 ± 2.7 weeks) were unexposed. In the adjusted models, seven measurements were smaller ( < .05) in opioid-exposed fetuses than in unexposed fetuses: cerebral frontooccipital diameter (93.8 ± 7.4 vs 95.0 ± 8.6 mm), bone biparietal diameter (79.0 ± 6.0 vs 80.3 ± 7.1 mm), brain biparietal diameter (72.9 ± 7.7 vs 74.1 ± 8.6 mm), corpus callosum length (37.7 ± 4.0 vs 39.4 ± 3.7 mm), vermis height (18.2 ± 2.7 vs 18.8 ± 2.6 mm), anteroposterior pons measurement (11.6 ± 1.4 vs 12.1 ± 1.4 mm), and transverse cerebellar diameter (40.4 ± 5.1 vs 41.4 ± 6.0 mm). In addition, in the adjusted model, the frontoocccipital index was larger ( = .02) in opioid-exposed fetuses (0.04 ± 0.02) than in unexposed fetuses (0.04 ± 0.02). Remaining measures and indexes were not significantly different between the two groups ( > .05). Fetal motion, cervical length, and deepest vertical pocket of amniotic fluid were not significantly different ( > .05) between groups. Opioid-exposed fetuses, compared with unexposed fetuses, showed higher frequencies of both breech position (21% vs 3%, = .03) and increased amniotic fluid volume (29% vs 8%, = .04). Fetuses with opioid exposure in utero had a smaller brain size and altered fetal physiology. The findings provide insight into the impact of prenatal opioid exposure on fetal brain development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975088PMC
http://dx.doi.org/10.2214/AJR.22.28357DOI Listing

Publication Analysis

Top Keywords

opioid-exposed fetuses
28
opioid exposure
20
fetuses
16
unexposed fetuses
16
fetuses opioid
12
case-control study
8
brain development
8
exposure utero
8
biometric measurements
8
additional pregnancy-related
8

Similar Publications

Article Synopsis
  • Neonatal Opioid Withdrawal Syndrome (NOWS) occurs when infants are exposed to opioids in utero, leading to symptoms like irritability and feeding issues, and can result in long-term health problems and increased mortality.
  • A study assessed DNA methylation of drug transporter genes in placental samples from mothers with varying levels of opioid exposure, revealing significant methylation changes in both solute carrier (SLC) and ATP-binding cassette (ABC) transporters, alongside protein kinase C (PKC) genes.
  • Findings suggest that these epigenetic changes could help explain drug resistance and improve treatment outcomes for infants suffering from NOWS.
View Article and Find Full Text PDF

Background: Buprenorphine-naloxone treatment may confer substantial benefits for the treatment of opioid use disorder (OUD) during pregnancy including lower risk for overdose/death, less diversion potential and reduced use of other substances. Treatment may also result in less severe Neonatal Abstinence Syndrome (NAS), but little is known about the effects of this medication on fetal neurodevelopment.

Methods: The purpose of the current study is to evaluate neurobehaviors among fetuses exposed to buprenorphine-naloxone at four time points over the second and third trimesters of gestation in pregnant women with OUD on buprenorphine-naloxone therapy.

View Article and Find Full Text PDF

Background And Purpose: While the adverse neurodevelopmental effects of prenatal opioid exposure on infants and children in the United States are well described, the underlying causative mechanisms have yet to be fully understood. This study aims to compare quantitative volumetric and surface-based features of the fetal brain between opioid-exposed fetuses and unexposed controls by using advanced MR imaging processing techniques.

Materials And Methods: This is a multi-institutional IRB-approved study in which pregnant women with and without opioid use during the current pregnancy were prospectively recruited to undergo fetal MR imaging.

View Article and Find Full Text PDF

DTI of Opioid-Exposed Fetuses Using ComBat Harmonization: A Bi-Institutional Study.

AJNR Am J Neuroradiol

September 2023

From the Department of Radiology and Medical Imaging (J.A.D., U.D.N., B.M.K.-F., W.Y.), Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Background And Purpose: The underlying mechanisms leading to altered cognitive, behavioral, and vision outcomes in children with prenatal opioid exposure are yet to be fully understood. Some studies suggest WM alterations in infants and children with prenatal opioid exposure; however, the time course of WM changes is unknown. We aimed to evaluate differences in diffusion tensor imaging MRI parameters in the brain between opioid exposed fetuses and normal controls.

View Article and Find Full Text PDF

effects of opioids on fetal growth.

J Matern Fetal Neonatal Med

December 2023

College of Medicine, Central Michigan University, Mount Pleasant, MI, USA.

Article Synopsis
  • Antenatal opioid use is linked to significant reductions in fetal growth parameters, such as head circumference and limb length, as observed during anatomy ultrasounds at 18-22 weeks' gestation.
  • *Pregnant women using opioids were compared to a control group without opioid exposure, and growth deficits were notably present in the opioid-exposed group, particularly with head circumference and biparietal diameter.
  • *The study underscores the need for greater awareness of the potential growth restrictions in fetuses due to prenatal opioid exposure, as it was associated with five times more instances of intrauterine growth restriction (IUGR).*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!